Progress in the study on COVID
10.11817/j.issn.1672-7347.2020.200322
- Author:
Jiajun ZHOU
1
;
Yongwu YU
2
;
Ling ZHANG
3
Author Information
1. Blood Purification Center, First Affiliated Hospital, Wannan Medical College, Wuhu Anhui 241000. zhjj1008@163.com.
2. Chui Yangliu Hospital Affiliated to Tsinghua University, Beijing 100022.
3. Department of Nephrology, China-Japan Friendship Hospital, Beijing 100029, China. zhangling5@medmail.com.cn.
- Publication Type:Journal Article
- Keywords:
angiotensin converting enzyme 2;
coronavirus disease 2019;
cytokine storm;
kidney injury
- MeSH:
Betacoronavirus;
COVID-19;
Coronavirus Infections/epidemiology*;
Humans;
Kidney;
Pandemics;
Pneumonia, Viral/epidemiology*;
SARS-CoV-2
- From:Journal of Central South University(Medical Sciences)
2020;45(10):1241-1246
- CountryChina
- Language:English
-
Abstract:
Coronavirus disease 2019 (COVID-19) is now a major public health problem worldwide. Infectivity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is extremely strong. The one major target of the virus is the lung, which leads to the deaths of respiratory distress syndrome and multiple organ failure. The kidney is also one of the main organs attacked by viruses, which directly damage the renal tubules through angiotensin converting enzyme-2 and cause cytokine storm, resulting in kidney damage and increasing the risk of death in the patients. Early investigation of risk factors for kidney injury, detection of kidney injury indicators, timely supporting treatment and renal replacement therapy for the existence of kidney injury patients are useful for reducing the mortality rate of COVID-19 patients.
